Mentioned by Stuart Roberts (ex Bell Potter analyst) today in...

Mentioned by Stuart Roberts (ex Bell Potter analyst) today in his new blog, last paragraph:

Then again, as with just about every US biotech, there’s an Australian comparable that’s a whole lot cheaper. Alchemia (ASX: ACL) delivers irinotecan using hyaluronic acid (HA) for better targeting. Because HA gets into cancer cells via CD44, we can confidently say that Alchemia’s product is knocking out cancer stem cells. And the product, called HA-Irinotecan, is in Phase III in metastatic colorectal cancer for second line therapy off the back of a doubling in PFS at Phase II. How much would you expect to pay for all this? At the moment you can get it for A$136m.

http://ozbiobuzz.blogspot.com.au/